Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
$2.45
-$0.02(-10.62%)
At close: 4:00 PM EST
$2.45
-$0.02(-10.62%)
Day’s Range― - ―
52-Week Range$2.15 - $7.77
Previous CloseN/A
Volume8.80M
Average Volume (3M)23.61K
Market Cap
$14.40M
Enterprise Value$21.29M
Total Cash (Recent Filing)$20.88M
Total Debt (Recent Filing)$10.15M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 27, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding4,351,358
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue18.03
Enterprise Value/Gross Profit23.99
Enterprise Value/Ebitda-12.72
Forecast
1Y Price Target
$12.00Price Target Upside389.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Marketed Product With Partner CommercializationHaving an approved product (APHEXDA) commercialized by external partners provides a recurring royalty/profit-share revenue stream and lowers direct commercialization burden. This supports durable income generation potential and lets management focus resources on R&D and pipeline advancement over the medium term.
GLIX1 Program: First-in-human Trial And Broad PatentInitiation of a first-in-human Phase 1/2a trial plus a U.S. patent extending protection to 2040 materially increases long-term pipeline value and exclusivity. Combined with a Hemispherian collaboration and top U.S. centers participating, this strengthens BioLineRx's strategic positioning in neuro-oncology and potential future revenue streams.
Legal Overhang Removed By Arbitration WinA final arbitration award in BioLineRx's favor eliminates a contingent ~$7.2M claim and related uncertainty, clarifying licensing obligations for motixafortide. Removing this legal overhang improves contract stability and reduces the likelihood of a material unexpected cash outflow or distraction for management.
Bears Say
Severe Revenue DeclineA roughly 91% revenue drop in 2025 indicates highly volatile and depressed top-line performance, undermining margin sustainability and recurring cash generation. Such a collapse weakens the company's ability to fund operations organically and increases reliance on partnerships, milestones, or external financing over the medium term.
Persistent Negative Cash FlowOperating and free cash flows remain structurally negative despite a meaningful improvement in operating burn. Continued negative FCF and funding needs constrain capital allocation to development programs and heighten dilution or refinancing risk if external funding or milestone receipts do not materialize in the coming quarters.
Compressed Equity And Meaningful LeveragePositive equity exists but has materially compressed versus prior years while debt remains meaningful relative to equity. This leverage profile reduces financial flexibility to absorb setbacks, increases refinancing risk if losses persist, and limits capacity for aggressive development spending without external capital.
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.15 and its highest was $7.77 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $14.40M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is May 27, 2026 which is in 17 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Mar 23, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.115.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -1.04.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,351,358 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went down -12.453%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BLRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.View all BLRX earnings summariesBLRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(389.80% Upside)
Technical Analysis
Synlogic
―
Moleculin Biotech
―
Citius Pharmaceuticals
―
Chemomab Therapeutics
―
Passage Bio
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors